Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.

H. Wilke(Kliniken Essen-Mitte), H. Poliwoda, M Freund, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), P. Preusser(University Hospital Münster), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), C. Schöber

PubMed

January 1, 1988

Cited by 5

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

|The Lancet Oncology|2012|526

Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis

|Genes & Development|2009|351

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

|Journal of Clinical Oncology|2007|281